As reported on PharmaBiz, AtaiBeckley has announced a key milestone in the development of its investigational depression therapy, VLS-01, with the final participant now dosed in the company’s Phase 2b ELUMINA study. The trial is evaluating the safety and effectiveness of VLS-01 in adults with treatment-resistant depression (TRD), a condition affecting patients who have not responded adequately to existing antidepressant therapies.
The global study enrolled 156 participants and is expected to generate topline results in the fourth quarter of 2026. The completion of dosing marks the transition into the follow-up and data analysis stages of the program.
Trial Design
ELUMINA is a randomized, double-blind, placebo-controlled, multicenter Phase 2b study designed to assess repeated administration of VLS-01. Participants were assigned in equal proportions to receive either VLS-01 or placebo through a buccal transmucosal film, a formulation designed to deliver medication through the inner cheek.
During the placebo-controlled portion of the study, patients receive two administrations separated by two weeks, followed by a 12-week monitoring period evaluating depressive symptoms, safety outcomes, and tolerability. Afterward, participants enter an additional treatment phase in which they receive a third dose of VLS-01 at one of two dose strengths, allowing researchers to further characterize dose-related effects.
Future Development Plans
According to AtaiBeckley leadership, positive Phase 2 findings could support advancement of VLS-01 into a Phase 3 program targeting major depressive disorder (MDD). The company believes the biological mechanisms underlying treatment-resistant depression and broader depressive disorders overlap sufficiently to justify further investigation in a larger MDD population.
The company is also exploring generalized anxiety disorder (GAD) as a potential future indication. Executives highlighted both the significant unmet clinical need in anxiety disorders and the therapy’s design, which is intended to fit within an approximately two-hour treatment session, potentially making it suitable for repeated administration in clinical settings.
About VLS-01
VLS-01 is an investigational oral transmucosal film containing N,N-dimethyltryptamine (DMT), a serotonergic compound being studied for its potential antidepressant effects. The therapy is designed to act on multiple serotonin receptor subtypes, including 5-HT1, 5-HT2, 5-HT6, and 5-HT7 receptors.
Researchers are investigating whether VLS-01 can provide rapid and sustained symptom improvement while maintaining an acceptable safety and tolerability profile. The treatment has been developed to align with existing interventional psychiatry care models, potentially facilitating integration into clinical practice if approved.
VLS-01 has not been approved by the U.S. Food and Drug Administration or any other regulatory authority and remains under clinical investigation.
The completion of dosing in ELUMINA represents an important step for AtaiBeckley’s depression program, with forthcoming Phase 2b results expected to help determine the future clinical path for VLS-01 across depression and potentially anxiety-related disorders.
